Adverse reactions associated with penicillins, carbapenems, monobactams, and clindamycin: A retrospective population-based study

Publication date: Available online 9 December 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Emily H. Liang, Lie H. Chen, Eric MacyAbstractBackgroundLimited population-based data on penicillin-, carbapenem-, monobactam-, and clindamycin-associated reported adverse reactions exists.ObjectiveCollect data on penicillin, carbapenem, monobactam, and clindamycin usage and associated adverse reactions.MethodsData from 1-1-2009 to 12-31-2017 in Kaiser Permanente Southern California was collected.ResultsThere were 6,144,422 unique individuals, mean age 33.6 ± 21.1 years, 52.2% females, with at least one healthcare visit during the 9-year study interval, for a total of 37,387,313 patient-years of follow-up. This population was exposed to 5,617,402 courses of oral penicillins, 370,478 courses of parenteral penicillins, 59,645 courses of parenteral carbapenems or monobactams, 817,232 courses of oral clindamycin, and 215,880 courses of parenteral clindamycin. New penicillin allergies were reported more commonly after parenteral (0.85%) compared to oral (0.74%) exposures (p
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

This article provides highlights of the clinically impactful original studies and reviews published in The Journal of Allergy and Clinical Immunology: In Practice in 2019 on the subjects of anaphylaxis, asthma, dermatitis, drug allergy, food allergy, immunodeficiency, immunotherapy, rhinitis/sinusitis, and urticaria/angioedema/mast cell disorders. Within each topic, practical aspects of diagnosis and management are emphasized. Treatments discussed include lifestyle modifications, allergen avoidance therapy, positive and negative effects of pharmacologic therapy, and various forms of immunologic and desensitization manageme...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Abstract Allergies to food and environmental antigens have steeply grown to epidemic proportions. IgE antibodies are key mediators of allergic disease, including life-threatening anaphylaxis. There is now compelling evidence that one of the hallmarks of anaphylaxis-inducing IgE molecules is their high affinity for allergen, and the cellular pathway to high-affinity IgE is typically through sequential switching of IgG B cells. Further, in contrast to the previously held paradigm that a subset of CD4+ T cells called Th2 cells promotes IgE responses, recent studies suggest that T follicular helper cells are crucial f...
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Tags: J Leukoc Biol Source Type: research
We have prepared a case that highlights the relationship between a patient ’s emotional state and the potential for systemic allergic reactions including anaphylaxis in a heretofore stable patient receiving maintenance subcutaneous allergen immunotherapy (SCIT) for treatment of allergic rhinoconjunctivitis (ARC) and mild persistent asthma.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Challenging Clinical Cases Source Type: research
Hey guys, had a patient with sulfa/sulfonamides allergy who I dispensed Meloxicam. Pt states that sulfa is in meloxicam structure so she is having anaphylactic reaction due to taking Meloxicam 8 hours earlier I checked Lexicom/Clinical pharmacology, and I just cant find it being as contraindication... Of course, pt is threatening to go to a hospital/sue/etc... Am I overlooking it as a contraindication? Can you guys double check me?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pharmacy Source Type: forums
This study aimed to identify the phenotype and immunologic findings in Korean children with barley allergy. METHODS: Forty-two participants with a history of ingesting barley who underwent serum specific immunoglobulin E to barley (barley-sIgE) assay at the Department of Pediatrics in Ajou Medical Center were enrolled through a retrospective analysis of medical records from March 2008 to February 2018. The demographic characteristics, symptoms, and immunologic parameters of the patients were assessed. RESULTS: Twenty subjects presented with clinical barley allergy (B-allergic group), and 22 were atopic controls w...
Source: J Korean Med Sci - Category: General Medicine Authors: Tags: J Korean Med Sci Source Type: research
AbstractPurpose of ReviewBiologic agents are new treatment options for chronic inflammatory diseases and cancers. As a result of their unique mechanism of action, they are more effective and less toxic treatment option and their clinical usage is increasing. While they are more commonly used, various adverse effects have been observed including life-threatening ones, including anaphylaxis. The aim of this review is to distinguish the anaphylaxis from other hypersensitivity reactions (HSR) and provide a management algorithm for the anaphylactic reactions induced by biological agents.Recent FindingsMany case reports and seri...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Publication date: Available online 16 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Matthew S. Krantz, Yiwei Liu, Elizabeth J. Phillips, Cosby A. Stone
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusions. Although there was no increase in Api m10 sIgG4 levels after 1 year bVIT, we did not observe relevant differences in other outcomes between patients with predominant Api m1 or Api m10 sensitization. PMID: 31939631 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Lisa M. Bartnikas, Scott H. Sicherer
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Ru-Xin Foong, Paul J. Turner, Adam T. Fox
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Clindamycin | Penicillin | Study